Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Ibrutinib & Waldenström's Macroglobulinemia

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Ibrutinib was the first BTK inhibitor to receive FDA approval for this disease. It is the only FDA/EMA approved agent.
Despina et al. 2020 Expert Opinion on Emerging Drugs 25: 433-444
Sarosiek et al. 2022 Expert Review of Anticancer Therapy 22(5): 471-478

Emerging drugs for the treatment of Waldenström macroglobulinemia
Despina et al. 2020 Expert Opinion on Emerging Drugs 25: 433-444
Review
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
Treon et al. 2018
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
Treon et al. 2021
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstr¨ om Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Dimopoulos et al. 2023 J Clin Oncol 41:5099-5106

7/1/2026